Claims
- 1. A method of inhibiting an inflammatory response in a mammal, the method comprising administering to the mammal a therapeutically effective amount of Hsp 27.
- 2. A method of inducing IL-10 production in a mammal, the method comprising administering to the mammal an effective amount of Hsp 27.
- 3. A method of inducing IL-12 production in a mammal, the method comprising administering to the mammal an effective amount of Hsp 27.
- 4. A method of simultaneously inducing IL-10 production and IL-12 production in a mammal, the method comprising administering to the mammal an effective amount of Hsp 27.
- 5. The method of claim 1, wherein the therapeutically effective amount is 1 μg/kg to 160 μg/kg.
- 6. The method of claim 5, wherein the therapeutically effective amount is 2 μg/kg to 80 μg/kg.
- 7. The method of claim 6, wherein the therapeutically effective amount is 4 μg/kg to 40 μg/kg.
- 8. An anti-inflammatory composition comprising an effective amount of Hsp 27 and a pharmaceutically acceptable carrier.
- 9. A method of promoting dendritic cell maturation, the method comprising:
isolating monocytes from blood without triggering activation; culturing the monocytes ex vivo; inducing conversion of the monocytes into immature dendritic cells; and contacting the dendritic cells with an effective amount of Hsp27 for an effective length of time, thereby promoting maturation of the dendritic cells.
- 10. The method of claim 9, wherein inducing conversion of the monocytes into immature dendritic cells comprises culturing the monocytes in a medium comprising IL-4 and GMCSF for an effective conversion time.
- 11. The method of claim 10, wherein the effective conversion time is 2 to 5 days.
- 12. The method of claim 9, wherein the effective amount of Hsp27 is 0.1 μg/ml to 500 μg/ml.
- 13. The method of claim 9, wherein the effective amount of Hsp27 is 1 μg to 100 μg.
- 14. The method of claim 9, wherein the effective amount of Hsp27 is 5 μg to 50 μg.
- 15. A method of enhancing an immune system response in a human patient, the method comprising:
collecting a sample of blood from the patient; isolating monocytes from the blood without triggering activation of the monocytes; culturing the monocytes ex vivo; inducing conversion of the monocytes into immature dendritic cells; promoting maturation of the dendritic cells by contacting the dendritic cells with an effective amount of Hsp27 for an effective length of time; and reintroducing the dendritic cells into the patient.
- 16. The method of claim 15, further comprising the step of contacting the dendritic cells with an antigen after promoting maturation of the dendritic cells, and before reintroducing the dendritic cells into the patient.
- 17. The method of claim 16, wherein the antigen is selected from the group consisting of a human tumor antigen, a bacterial antigen, and a viral antigen.
STATEMENT AS TO FEDERALLY-SPONSORED RESEARCH
[0001] Work on the invention was funded in part by the federal government (NIH 2RO 1 GM 36214-13). Therefore, the government may have certain rights in the invention.
Provisional Applications (1)
|
Number |
Date |
Country |
|
60168834 |
Dec 1999 |
US |